Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 /CDK Pathway Mutations
Details
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Eligibility
You can join if...
Inclusion Criteria:
Histologically proven intracranial meningioma as documented by
central pathology review
Presence of SMO, PTCH1, NF2, CDKN2A, AKT1, PIK3CA, PTEN
mutations, CDKN2A copy number loss, CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1
copy number gain in tumor sample as documented specifically by the central laboratory
Male or female who are not pregnant and not nursing
Exclusion Criteria:
Patients who have active bacterial infection
Patients who have history of heart diseases as described by the study protocol